Dr James Overell

  • Honorary Clinical Associate Professor (School of Medicine, Dentistry & Nursing)

email: James.Overell@glasgow.ac.uk

Medicine - Clinical Neuroscience, BRC - Sir Graeme Davies

Publications

List by: Type | Date

Jump to: 2021 | 2017 | 2016 | 2011 | 2007
Number of items: 6.

2021

Brown, J. W. L. et al. (2021) Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, 20(9), pp. 709-720. (doi: 10.1016/S1474-4422(21)00179-4)

York, E. N. et al. (2021) MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis. Brain Communications, 3(4), fcab249. (doi: 10.1093/braincomms/fcab249) (PMID:34877533) (PMCID:PMC8643503)

2017

Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A. , van Doorn, P. and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12. (doi: 10.1111/jns.12194) (PMID:27801990)

2016

Kavanagh, D. et al. (2016) Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood, 128(24), pp. 2824-2833. (doi: 10.1182/blood-2016-05-715987) (PMID:27663672)

2011

Fitzpatrick, A.M., Mann, C.A., Barry, S. , Brennan, K., Overell, J.R. and Willison, H.J. (2011) An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 16(2), pp. 84-91. (doi: 10.1111/j.1529-8027.2011.00328.x)

2007

Overell, J.R., Hsieh, S.-T., Odaka, M., Yuki, N. and Willison, H.J. (2007) Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database of Systematic Reviews(1), CD004761. (doi: 10.1002/14651858.CD004761.pub2)

This list was generated on Sun Sep 25 21:14:41 2022 BST.
Jump to: Articles
Number of items: 6.

Articles

Brown, J. W. L. et al. (2021) Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, 20(9), pp. 709-720. (doi: 10.1016/S1474-4422(21)00179-4)

York, E. N. et al. (2021) MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis. Brain Communications, 3(4), fcab249. (doi: 10.1093/braincomms/fcab249) (PMID:34877533) (PMCID:PMC8643503)

Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A. , van Doorn, P. and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12. (doi: 10.1111/jns.12194) (PMID:27801990)

Kavanagh, D. et al. (2016) Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood, 128(24), pp. 2824-2833. (doi: 10.1182/blood-2016-05-715987) (PMID:27663672)

Fitzpatrick, A.M., Mann, C.A., Barry, S. , Brennan, K., Overell, J.R. and Willison, H.J. (2011) An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 16(2), pp. 84-91. (doi: 10.1111/j.1529-8027.2011.00328.x)

Overell, J.R., Hsieh, S.-T., Odaka, M., Yuki, N. and Willison, H.J. (2007) Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database of Systematic Reviews(1), CD004761. (doi: 10.1002/14651858.CD004761.pub2)

This list was generated on Sun Sep 25 21:14:41 2022 BST.